Sol-Gel Technologies Ltd. (SLGL): Total Liabilities
$7.11M
As of 2025-12-31
+17.2%
3-year compound annual growth
-3.1%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $7.11M | +1.6% | 2026-03-19, Balance as of period end |
| 2024-12-31 | $7.00M | +5.3% | 2026-03-19, Balance as of period end |
| 2023-12-31 | $6.64M | +50.5% | 2025-04-29, Balance as of period end |
| 2022-12-31 | $4.42M | -67.5% | 2024-03-13, Balance as of period end |
| 2021-12-31 | $13.60M | +63.6% | 2023-03-10, Balance as of period end |
| 2020-12-31 | $8.31M | -5.9% | 2022-04-07, Balance as of period end |
| 2019-12-31 | $8.84M | +53.1% | 2021-03-04, Balance as of period end |
| 2018-12-31 | $5.77M | -91.5% | 2020-03-24, Balance as of period end |
| 2017-12-31 | $68.01M | +60.7% | 2019-03-21, Balance as of period end |
| 2016-12-31 | $42.32M | n/a | 2018-03-26, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Sol-Gel Technologies Ltd. (SLGL) | 2025-12-31 | $7.11M | +1.6% |
| Evofem Biosciences, Inc. (EVFM) | 2025-12-31 | $89.71M | -0.6% |
| Scynexis Inc (SCYX) | 2025-12-31 | $9.65M | -72.9% |
| CASI Pharmaceuticals, Inc. (CASIF) | 2025-12-31 | $62.93M | +21.4% |
| NewAmsterdam Pharma Co N.V. (NAMS) | 2025-12-31 | $85.85M | -19.9% |
| uniQure N.V. (QURE) | 2025-12-31 | $626.01M | +11.1% |
| Alumis Inc. (ALMS) | 2025-12-31 | $110.64M | +36.8% |
| Entrada Therapeutics, Inc. (TRDA) | 2025-12-31 | $71.25M | -27.0% |
| Opus Genetics, Inc. (IRD) | 2025-12-31 | $34.90M | +208.9% |
Compare SLGL, EVFM, SCYX, CASIF side by side · Screen every company in Pharmaceutical Preparations ↗